What is the impact of noradrenaline on REM sleep and the occurrence of nightmares?

Noradrenaline's Role in REM Sleep and Nightmares

Noradrenaline (norepinephrine) actively suppresses REM sleep and elevated noradrenergic activity is directly implicated in the pathophysiology of nightmares, which is why alpha-1 adrenergic receptor blockade with prazosin can reduce nightmare frequency and intensity. 1

Mechanism of Noradrenaline in REM Sleep Regulation

Noradrenergic Suppression of REM Sleep

• Noradrenaline from locus coeruleus (LC) neurons acts on pedunculo-pontine tegmentum (PPT) REM-ON neurons to actively prevent REM sleep from occurring during wakefulness and NREM sleep. 2

• When LC noradrenergic neurons are experimentally downregulated using tyrosine hydroxylase-siRNA in rats, REM sleep increases significantly, confirming that noradrenaline is the primary neurotransmitter preventing REM sleep appearance. 2

• Noradrenergic neurons are maximally active during waking, moderately active during NREM sleep (with infraslow oscillations), and virtually silent during REM sleep. 3, 4, 5

• The A1/C1, A2, and A5 brainstem noradrenergic cell groups (not just the LC) contribute significantly to REM sleep inhibition, with up to 40% of these neurons showing activation markers during REM sleep deprivation. 3

Dose-Dependent Effects on Sleep Architecture

• Low-dose noradrenergic agonism (clonidine 25 μg) paradoxically increases REM sleep by acting presynaptically on LC autoreceptors to reduce noradrenaline release, while medium doses (150 μg) decrease REM sleep through postsynaptic effects. 6

• This biphasic response demonstrates that the level of noradrenergic tone critically determines REM sleep propensity. 6

Noradrenaline and Nightmare Pathophysiology

Direct Link Between Noradrenaline and Nightmares

• Drugs affecting norepinephrine, serotonin, and dopamine neurotransmission can produce nightmares, and withdrawal of REM-suppressing agents is associated with nightmare occurrence. 1

• The hyperarousal symptom cluster in PTSD, which includes nightmares, is linked to excessive noradrenergic activity, though the relationship between non-PTSD nightmares and hyperarousal remains incompletely characterized. 1

• Nightmare disorder patients show increased heartbeat-evoked potentials (HEPs) specifically during REM sleep in frontal regions, indicating elevated emotional arousal and brain-body interoceptive processing during REM periods when nightmares occur. 7

Noradrenergic Oscillations During Sleep

• During NREM sleep, noradrenaline exhibits infraslow oscillations (0.02-0.03 Hz) that are synchronized with other neuromodulators (serotonin, acetylcholine), and these oscillations shape sleep micro-architecture including micro-arousals and sleep spindles. 4, 8, 5

• The amplitude of noradrenaline oscillations during NREM sleep determines memory consolidation quality: prolonged descents promote spindle-enriched sleep and REM sleep but also associate with awakenings, while shorter descents maintain NREM continuity. 8

• Noradrenaline levels during consolidated NREM sleep can exceed those of quiet wakefulness, maintaining sensory vigilance through thalamic modulation via α1- and β-adrenergic receptors. 5

Clinical Implications: Prazosin for Nightmare Treatment

Mechanism of Action

• Prazosin, an alpha-1 adrenergic receptor antagonist, blocks the arousal-promoting effects of noradrenaline that are implicated in PTSD-associated nightmares. 1

• Alpha-1 adrenergic receptors regulate multiple phenomena implicated in PTSD pathogenesis, including sleep and nightmare generation. 1

Evidence for Efficacy

• Multiple randomized controlled trials demonstrated that prazosin (doses ranging from 3-20 mg, typically 9-15 mg) significantly reduces nightmare frequency and intensity in both military veterans and civilians with PTSD-associated nightmares. 1

• In an 8-week RCT of 34 veterans, prazosin 13 mg/day reduced the CAPS distressing dreams item by over 50% compared to 15% with placebo (posttreatment scores: prazosin 3.2 ± 2.6 vs placebo 5.2 ± 2.2). 1

• A 15-week RCT in active-duty soldiers showed prazosin significantly improved all three primary outcomes: CAPS nightmare item decreased by 3.1 ± 0.3 (prazosin) vs 1.2 ± 0.3 (placebo), with 64% vs 27% showing marked/moderate improvement. 1

Important Caveats

• A large 2018 VA study of 304 participants found no significant difference between prazosin (mean 14.8 mg) and placebo at 10 or 26 weeks, leading to downgrading of the recommendation from "suggested" to "may be used." 1

• Concurrent SSRI use may reduce prazosin efficacy: in one study, total CAPS scores decreased by 30.1 ± 3.8 in patients not taking SSRIs versus only 9.6 ± 6.8 in those on maintenance SSRIs. 1

• The American Academy of Sleep Medicine now states prazosin "may be used" rather than providing a stronger recommendation, though it remains the first-choice pharmacologic agent in clinical practice. 1

Practical Prescribing

• Start prazosin at low doses (1 mg at bedtime) and titrate based on nightmare response and tolerability, with effective doses typically ranging from 1-20 mg. 1

• Monitor for orthostatic hypotension and dizziness, particularly during dose escalation, though serious adverse events (falls, syncope) are rare. 1

• Consider avoiding or carefully monitoring prazosin in patients on maintenance antidepressants, as this combination may reduce efficacy. 1

Consequences of REM Sleep Loss and Elevated Noradrenaline

• REM sleep deprivation causes sustained elevation of noradrenaline, which stimulates neuronal Na-K ATPase activity while paradoxically inhibiting glial Na-K ATPase, disrupting neuronal homeostasis. 9

• Chronic REM sleep loss with persistently elevated noradrenaline contributes to oxidative neuronal damage, loss of synapses, and potentially neurodegenerative processes. 10

• Blocking alpha-1 adrenoceptors with prazosin prevents REM sleep deprivation-induced molecular changes (Na-K ATPase alterations), confirming that noradrenaline mediates many REM sleep loss-associated symptoms. 2, 9